{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:03:21Z","timestamp":1782489801076,"version":"3.54.5"},"reference-count":74,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","bprclinrheum.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.berh.2016.09.001","type":"journal-article","created":{"date-parts":[[2016,9,22]],"date-time":"2016-09-22T03:16:57Z","timestamp":1474514217000},"page":"296-303","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Approach to the patients with inadequate response to colchicine in familial Mediterranean fever"],"prefix":"10.1016","volume":"30","author":[{"given":"Ahmet","family":"G\u00fcl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2016.09.001_bib1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/archinte.1958.00260190052007","article-title":"Familial Mediterranean fever","volume":"102","author":"Heller","year":"1958","journal-title":"AMA Arch Intern Med"},{"key":"10.1016\/j.berh.2016.09.001_bib2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0002-9343(67)90167-2","article-title":"Familial Mediterranean fever. A survey of 470 cases and review of the literature","volume":"43","author":"Sohar","year":"1967","journal-title":"Am J Med"},{"key":"10.1016\/j.berh.2016.09.001_bib3","first-page":"797","article-title":"The International FMF Consortium","volume":"90","author":"Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.berh.2016.09.001_bib4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/ng0997-25","article-title":"A\u00a0candidate gene for familial Mediterranean fever","volume":"17","year":"1997","journal-title":"Nat Genet"},{"key":"10.1016\/j.berh.2016.09.001_bib5","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/annrheumdis-2014-206844","article-title":"Evidence-based recommendations for genetic diagnosis of familial Mediterranean fever","volume":"74","author":"Giancane","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2016.09.001_bib6","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1136\/annrheumdis-2012-202774","article-title":"Increased NLRP3-dependent interleukin 1beta secretion in patients with familial Mediterranean fever: correlation with MEFV genotype","volume":"73","author":"Omenetti","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2016.09.001_bib7","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJM197410312911803","article-title":"A\u00a0controlled trial of colchicine in preventing attacks of familial mediterranean fever","volume":"291","author":"Zemer","year":"1974","journal-title":"N.\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2016.09.001_bib8","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJM197410312911804","article-title":"Colchicine therapy for familial mediterranean fever. A double-blind trial","volume":"291","author":"Dinarello","year":"1974","journal-title":"N.\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2016.09.001_bib9","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM198604173141601","article-title":"Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever","volume":"314","author":"Zemer","year":"1986","journal-title":"N.\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2016.09.001_bib10","first-page":"281","article-title":"Treatment of familial Mediterranean fever: colchicine and beyond","volume":"16","author":"Gul","year":"2014","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.berh.2016.09.001_bib11","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/art.1780401023","article-title":"Criteria for the diagnosis of familial Mediterranean fever","volume":"40","author":"Livneh","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2016.09.001_bib12","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.autrev.2014.01.045","article-title":"Diagnostic criteria of familial Mediterranean fever","volume":"13","author":"Berkun","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2016.09.001_bib13","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/art.1780340806","article-title":"Long-term colchicine treatment in children with familial Mediterranean fever","volume":"34","author":"Zemer","year":"1991","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2016.09.001_bib14","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1136\/annrheumdis-2012-202580","article-title":"MEFV mutations affecting pyrin amino acid 577 cause autosomal dominant autoinflammatory disease","volume":"73","author":"Stoffels","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2016.09.001_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf1471","article-title":"Familial autoinflammation with neutrophilic dermatosis reveals a regulatory mechanism of pyrin activation","volume":"8","author":"Masters","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.berh.2016.09.001_bib16","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.gene.2011.10.005","article-title":"The relative contribution of environmental and genetic factors to phenotypic variation in familial Mediterranean fever (FMF)","volume":"491","author":"Ben-Zvi","year":"2012","journal-title":"Gene"},{"key":"10.1016\/j.berh.2016.09.001_bib17","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.autrev.2012.07.025","article-title":"Incomplete response to colchicine in M694V homozygote FMF patients","volume":"12","author":"Lidar","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2016.09.001_bib18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1750-1172-9-3","article-title":"Colchicine-free remission in familial Mediterranean fever: featuring a unique subset of the disease-a case control study","volume":"9","author":"Ben-Zvi","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.berh.2016.09.001_bib19","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13023-015-0252-7","article-title":"Familial Mediterranean fever without MEFV mutations: a case-control study","volume":"10","author":"Ben-Zvi","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.berh.2016.09.001_bib20","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1136\/annrheumdis-2015-208671","article-title":"Development and initial validation of international severity scoring system for familial Mediterranean fever (ISSF)","volume":"75","author":"Demirkaya","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2016.09.001_bib21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.semarthrit.2005.02.002","article-title":"Evaluation of disease severity in familial Mediterranean fever","volume":"35","author":"Mor","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2016.09.001_bib22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0049-0172(91)90019-V","article-title":"Colchicine prophylaxis in familial Mediterranean fever: reappraisal after 15 years","volume":"20","author":"Ben-Chetrit","year":"1991","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2016.09.001_bib23","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1002\/art.38797","article-title":"Exertional leg pain in familial Mediterranean fever: a manifestation of an underlying enthesopathy and a marker of more severe disease","volume":"66","author":"Eshed","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2016.09.001_bib24","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1093\/rheumatology\/keu138","article-title":"Can colchicine response be predicted in familial Mediterranean fever patients?","volume":"53","author":"Ozcakar","year":"2014","journal-title":"Rheumatol Oxf"},{"key":"10.1016\/j.berh.2016.09.001_bib25","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1002\/art.22507","article-title":"Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever","volume":"56","author":"Touitou","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2016.09.001_bib26","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nrrheum.2016.55","article-title":"Autoinflammation: when is familial Mediterranean fever 'severe'?","volume":"12","author":"Lachmann","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2016.09.001_bib27","doi-asserted-by":"crossref","first-page":"426","DOI":"10.7326\/0003-4819-116-5-426_1","article-title":"Reversal of the nephrotic syndrome by colchicine in amyloidosis of familial Mediterranean fever","volume":"116","author":"Zemer","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.berh.2016.09.001_bib28","doi-asserted-by":"crossref","first-page":"795","DOI":"10.7326\/0003-4819-57-5-795","article-title":"Amyloidosis as the sole manifestation of familial Mediterranean fever (FMF). Further evidence of its genetic nature","volume":"57","author":"Blum","year":"1962","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.berh.2016.09.001_bib29","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1002\/art.27683","article-title":"Association of familial Mediterranean fever-related MEFV variations with ankylosing spondylitis","volume":"62","author":"Cosan","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2016.09.001_bib30","doi-asserted-by":"crossref","first-page":"8134","DOI":"10.1073\/pnas.1306352110","article-title":"Targeted resequencing implicates the familial Mediterranean fever gene MEFV and the toll-like receptor 4 gene TLR4 in Behcet disease","volume":"110","author":"Kirino","year":"2013","journal-title":"Proc Natl Acad Sci U. S. A"},{"key":"10.1016\/j.berh.2016.09.001_bib31","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1542\/peds.2006-1434","article-title":"Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement","volume":"119","author":"Kallinich","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.berh.2016.09.001_bib32","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.semarthrit.2013.04.011","article-title":"Evidence-based recommendations for the practical management of familial Mediterranean fever","volume":"43","author":"Hentgen","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2016.09.001_bib33","first-page":"1540","article-title":"Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in familial Mediterranean fever","volume":"34","author":"Tufan","year":"2007","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2016.09.001_bib34","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1053\/S0049-0172(03)00137-9","article-title":"Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization","volume":"33","author":"Lidar","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2016.09.001_bib35","first-page":"S1","article-title":"About colchicine compliance, resistance and virulence","volume":"27","author":"Ben-Chetrit","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2016.09.001_bib36","first-page":"137","article-title":"The familial Mediterranean fever (FMF) 50 score: does it work in a controlled clinical trial? Re-analysis of the trial of rilonacept for patients with colchicine-resistant or intolerant FMF","volume":"17","author":"Hashkes","year":"2015","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.berh.2016.09.001_bib37","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/annrheumdis-2013-204719","article-title":"FMF50: a score for assessing outcome in familial Mediterranean fever","volume":"73","author":"Ozen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2016.09.001_bib38","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7326\/0003-4819-157-8-201210160-00003","article-title":"Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial","volume":"157","author":"Hashkes","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.berh.2016.09.001_bib39","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s13075-015-0765-4","article-title":"Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever","volume":"17","author":"Gul","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2016.09.001_bib40","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/annrheumdis-2015-208690","article-title":"EULAR recommendations for the management of familial Mediterranean fever","volume":"75","author":"Ozen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2016.09.001_bib41","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature13449","article-title":"Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome","volume":"513","author":"Xu","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.berh.2016.09.001_bib42","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1007\/s11427-014-4758-3","article-title":"Immunological function of familial Mediterranean fever disease protein Pyrin","volume":"57","author":"Yang","year":"2014","journal-title":"Sci China Life Sci"},{"key":"10.1016\/j.berh.2016.09.001_bib43","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/ni.3457","article-title":"Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS","volume":"17","author":"Park","year":"2016","journal-title":"Nat Immunol"},{"key":"10.1016\/j.berh.2016.09.001_bib44","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-146-11-200706050-00023","article-title":"Treatment of familial Mediterranean fever with anakinra","volume":"146","author":"Belkhir","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.berh.2016.09.001_bib45","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/j.1365-2362.2007.01868.x","article-title":"Anakinra in two adolescent female patients suffering from colchicine-resistant familial Mediterranean fever: effective but risky","volume":"37","author":"Gattringer","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.berh.2016.09.001_bib46","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00431-007-0547-3","article-title":"The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever","volume":"167","author":"Calligaris","year":"2008","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.berh.2016.09.001_bib47","first-page":"489","article-title":"Anakinra suppresses familial Mediterranean fever crises in a colchicine-resistant patient","volume":"66","author":"Mitroulis","year":"2008","journal-title":"Neth J Med"},{"key":"10.1016\/j.berh.2016.09.001_bib48","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jbspin.2008.04.001","article-title":"Anakinra: new therapeutic approach in children with Familial Mediterranean Fever resistant to colchicine","volume":"75","author":"Roldan","year":"2008","journal-title":"Jt Bone Spine"},{"key":"10.1016\/j.berh.2016.09.001_bib49","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3899\/jrheum.100718","article-title":"Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine","volume":"38","author":"Ozen","year":"2011","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2016.09.001_bib50","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1007\/s00296-010-1474-6","article-title":"Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever","volume":"32","author":"Alpay","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.berh.2016.09.001_bib51","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/ckj\/sft164","article-title":"Colchicine-resistant familial Mediterranean fever in a renal transplantation patient: successful treatment with anakinra","volume":"7","author":"Celebi","year":"2014","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.berh.2016.09.001_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2014.01.065","article-title":"Long-term efficacy of interleukin-1 receptor antagonist (anakinra) in corticosteroid-dependent and colchicine-resistant recurrent pericarditis","volume":"164","author":"Finetti","year":"2014","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.berh.2016.09.001_bib53","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.nefro.2015.06.026","article-title":"Anakinra induces complete remission of nephrotic syndrome in a patient with familial mediterranean fever and amyloidosis","volume":"36","author":"Sevillano","year":"2016","journal-title":"Nefrologia"},{"key":"10.1016\/j.berh.2016.09.001_bib54","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3109\/03009742.2015.1127413","article-title":"Anakinra for the treatment of familial Mediterranean fever-associated spondyloarthritis","volume":"45","author":"Varan","year":"2016","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.berh.2016.09.001_bib55","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.semarthrit.2010.11.003","article-title":"Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature","volume":"41","author":"Meinzer","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2016.09.001_bib56","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1136\/ard.2010.146878","article-title":"The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and longstanding destructive arthritis","volume":"70","author":"Mitroulis","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2016.09.001_bib57","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/rheumatology\/kes021","article-title":"Canakinumab induces remission in a patient with resistant familial Mediterranean fever","volume":"51","author":"Hacihamdioglu","year":"2012","journal-title":"Rheumatol Oxf"},{"key":"10.1016\/j.berh.2016.09.001_bib58","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1002\/art.38777","article-title":"Canakinumab for the treatment of children with colchicine-resistant familial Mediterranean fever: a 6-month open-label, single-arm pilot study","volume":"66","author":"Brik","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2016.09.001_bib59","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3109\/14397595.2014.987437","article-title":"Interleukin-1 targeting treatment in familial Mediterranean fever: an experience of pediatric patients","volume":"25","author":"Basaran","year":"2015","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.berh.2016.09.001_bib60","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s10753-014-0004-1","article-title":"Efficacy of interleukin-1 targeting treatments in patients with familial mediterranean Fever","volume":"38","author":"Cetin","year":"2015","journal-title":"Inflammation"},{"key":"10.1016\/j.berh.2016.09.001_bib61","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10067-014-2772-2","article-title":"Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis","volume":"35","author":"Ozcakar","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2016.09.001_bib62","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2174\/0929867323666151117121706","article-title":"Colchicine, biologic agents and more for the treatment of familial mediterranean fever. The old, the new, and the rare","volume":"23","author":"Portincasa","year":"2016","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.berh.2016.09.001_bib63","first-page":"75","article-title":"Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature","volume":"10","author":"van der Hilst","year":"2016","journal-title":"Biologics"},{"key":"10.1016\/j.berh.2016.09.001_bib64","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10067-005-1122-9","article-title":"Familial Mediterranean fever responds well to infliximab: single case experience","volume":"25","author":"Ozgocmen","year":"2006","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2016.09.001_bib65","first-page":"435","article-title":"Etanercept in the treatment of arthritis in a patient with familial Mediterranean fever","volume":"24","author":"Sakallioglu","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2016.09.001_bib66","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/RHU.0b013e31823682f5","article-title":"Effects of anti-tumor necrosis factor agents for familial mediterranean fever patients with chronic arthritis and\/or sacroiliitis who were resistant to colchicine treatment","volume":"17","author":"Bilgen","year":"2011","journal-title":"J\u00a0Clin Rheumatol"},{"key":"10.1016\/j.berh.2016.09.001_bib67","doi-asserted-by":"crossref","first-page":"684","DOI":"10.3109\/s10165-011-0463-2","article-title":"Anti-TNF agents in familial Mediterranean fever: report of three cases and review of the literature","volume":"21","author":"Ozgocmen","year":"2011","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.berh.2016.09.001_bib68","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s00296-011-1855-5","article-title":"Successful treatment with anti-tumor necrosis factor (anti-TNF)-alpha of proteinuria in a patient with familial mediterranean fever (FMF) resistant to colchicine: anti-TNF drugs and FMF","volume":"32","author":"Erten","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.berh.2016.09.001_bib69","first-page":"102","article-title":"Late onset of Crohn's disease in familial Mediterranean fever: the necessity of anti-TNF treatment","volume":"15","author":"Kosmidou","year":"2014","journal-title":"J\u00a0Dig Dis"},{"key":"10.1016\/j.berh.2016.09.001_bib70","first-page":"225","article-title":"Newly diagnosed Crohn's disease in patient with familial Mediterranean fever","volume":"19","author":"Akar","year":"2016","journal-title":"Arch Iran Med"},{"key":"10.1016\/j.berh.2016.09.001_bib71","article-title":"Protracted febrile myalgia in a patient with familial Mediterranean fever and ankylosing spondylitis","author":"Eksioglu","year":"2016","journal-title":"J\u00a0Back Musculoskelet Rehabil"},{"key":"10.1016\/j.berh.2016.09.001_bib72","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.12776","article-title":"Tocilizumab is effective in a familial Mediterranean fever patient complicated with histologically proven recurrent fasciitis and myositis","author":"Umeda","year":"2015","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.berh.2016.09.001_bib73","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/rheumatology\/keu474","article-title":"Tocilizumab in the treatment of patients with AA amyloidosis secondary to familial Mediterranean fever","volume":"54","author":"Yilmaz","year":"2015","journal-title":"Rheumatol Oxf"},{"key":"10.1016\/j.berh.2016.09.001_bib74","doi-asserted-by":"crossref","first-page":"610","DOI":"10.3109\/14397595.2014.908810","article-title":"Successful treatment with humanized anti-interleukin-6 receptor antibody (tocilizumab) in a case of AA amyloidosis complicated by familial Mediterranean fever","volume":"26","author":"Hamanoue","year":"2016","journal-title":"Mod Rheumatol"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694216300481?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694216300481?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T05:34:18Z","timestamp":1601098458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694216300481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":74,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S1521694216300481"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2016.09.001","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Approach to the patients with inadequate response to colchicine in familial Mediterranean fever","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2016.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}